FOR IMMEDIATE RELEASE |
11 FEBRUARY 2015 |
CANCER UPDATE: IPP-204106
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, provides an update on its lead Cancer programme - IPP-204106.
As previously stated, the Phase I/IIa clinical trial with the next generation "polyplexed Nucant" formulation taking place in three European hospitals including the prestigious Institute Jules Bordet in Belgium, has been completed.
This Phase I/IIa study was a dose-finding adaptive study where the Nucant was associated with chondroitin sulfate, which has shown in preclinical studies a strong potentiating effect of the Nucant. The results demonstrate that the maximum tolerated dose with chondroitin sulfate was 9mg/kg. This was the primary objective of the study.
In preclinical studies it was indicated that a 1mg/kg equivalent human dose with chondroitin sulfate in a combination therapy using the cancer drug Gemcitabin demonstrated a massive reduction in tumour volume in mouse pancreatic cancer.
These Phase I/IIa results now allow ImmuPharma, from a regulatory perspective, to commence a Phase II study in pancreatic cancer using the optimum human dosage.
A further update on this new Phase II study will be given in due course.
-Ends-
For further information please contact:
ImmuPharma plc |
+ 44 (0) 20 7152 4080 |
Dimitri Dimitriou, Chief Executive Officer |
|
Dr Robert Zimmer, President and Chief Scientific Officer |
|
Richard Warr, Chairman |
|
Lisa Baderoon, Head of Investor Relations |
+ 44 (0) 7721 413496 |
|
|
Panmure, Gordon & Co., NOMAD & Broker |
+44 (0) 20 7886 2500 |
Hugh Morgan, Fred Walsh, Duncan Monteith |
|
